Ocugen to Highlight Gene Therapy Progress at Major July Conferences

Ocugen to Highlight Gene Therapy Progress at Major July Conferences

The inherited retinal disease (IRD) community is closely watching advancements in gene therapy, and upcoming industry conferences offer a crucial window into the latest developments. Ocugen, a biotechnology company focused on gene therapies for blindness diseases, has announced its participation in several key events this July, where it plans to share updates on its innovative modifier gene therapy platform and clinical programs. These presentations are important for patients, families, and advocates as they provide insights into potential future treatments for various IRDs.

According to a Yahoo Finance report published on July 1, 2026, Ocugen will be presenting at three significant gatherings:

• Piper Sandler Virtual Ophthalmology Day: On Friday, July 10, 2026, from 10:00–10:25 a.m. EDT, Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, is scheduled to participate in a fireside chat. A webcast of this presentation will be available on the Investors section of Ocugen's website, with a replay accessible for 30 days following the event.
• OIS (Ophthalmology Innovation Source) Retina Innovation Summit: On Tuesday, July 14, 2026, at 1:45 p.m. EDT, a panel discussion titled "Regenerative Approaches in Retinal Disease: From Genetic Repair to Functional Restoration" will feature Dr. Musunuri. This summit will take place in Montreal.
• ASRS (American Society of Retina Specialists) Meeting: On Friday, July 17, 2026, at the Palais des Congrès de Montréal, Ocugen-affiliated investigators are slated to present. Presentations will include the OCU410 Phase 2 ArMaDa 1-year results (8:21–8:24 a.m. EDT) and a Phase 1/2 OCU410 quantitative FAF/SD-OCT analysis with safety outcomes (8:24–8:27 a.m. EDT). OCU410 is a modifier gene therapy program targeting inherited retinal diseases such as Retinitis Pigmentosa and Leber Congenital Amaurosis.

These conferences serve as vital platforms for biotechnology companies to share their research and development progress with the scientific and investment communities. For the IRD community, these updates can offer hope and information about the pipeline of potential therapies. Ocugen's focus on a "modifier gene therapy platform" aims to address complex diseases that may be caused by imbalances in multiple gene networks, offering a gene-agnostic approach that could potentially benefit larger patient populations. This approach differs from traditional gene therapies that often target specific gene mutations.

The presentations, particularly those at the ASRS meeting concerning OCU410 Phase 2 results, could provide valuable insights into the therapy's safety and efficacy profile over a longer period. As Ocugen continues its development programs for inherited retinal diseases, the community looks forward to learning more about how these advancements could translate into new treatment options.